adenocarcinoma of esophagus and stomach junction
Conditions
Interventions
Case series:After induction chemotherapy (TS protocol 1 cycle) and concurrent chemotherapy, radical surgical resection will be given
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 75 years male and female; 2) Gastroscopy, barium meal, CT,MRI, endoscopic ultrasonography, upper gastrointestinal contrast-enhanced ultrasonography and pathology were diagnosed as carcinoma of esophagus and stomach. The 2010 version of UICC/AJCC staging standard, that is, II~IVA stage lesion (T2 = 3 months in the eastern tumor collaboration group; 6) The main organ function is normal, that is to say, the main organ function is normal, that is to say, the blood routine examination standard should be in accordance with: HB = 4.0x10^9/L is not allowed to meet the admission standard, absolute value of neutrophils > 2.0x10^9/L, PLT>=100x 10^9/L) biochemical examination should meet the following criteria: Crea and BIL <= 1.0 times normal value upper limit, ALT and AST <= 2.5 times normal value upper limit; 7) Women of childbearing age must undergo pregnancy tests (serum or urine) 7 days before admission, with negative results, and are willing to use appropriate methods of birth control during the trial and 8 weeks after the last administration. For men, surgical sterilization or consent to use appropriate methods of birth control during the trial or 8 weeks after the last administration; 8) the subjects volunteered to join the study and signed the informed consent form with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1) It is currently under treatment or has been previously treated with anti-tumor regimen (e.g., radiotherapy, chemotherapy, intervention, targeting, immunotherapy, surgery, etc.); 2) There are other malignancies in the past or at the same time, except for skin basal cell carcinoma and cervical carcinoma of the cervix that have been cured; 3) Allergic to paclitaxel, tegiol or similar drugs; 4) There are severe digestive tract diseases that affect the absorption of oral chemotherapy drugs, such as chronic inflammatory bowel disease; 5) Patients with a history of gastric perforation within 6 months; 6) The clinical manifestations include obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency, severe cardiac valvular disease, or severe lung function impairment; or the blood system, the liver and the kidney function is impaired, the chemotherapy and chemotherapy can not be tolerated; or the patients with severe bone marrow function failure; or the infection that is not controlled can be combined. 7) Uncontrolled mentally ill subjects; 8) Subjects with pregnancy or lactation; 9) unwilling or unable to cooperate with the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete remission rate; | — |
Countries
China
Contacts
Public ContactYaqin Zhao
West China Hospital, Sichuan University
Outcome results
None listed